Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03581877 · ClinicalTrials.gov registry record · Phase 4
Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE
A Phase 4 study of Pulmonary Hypertension and Pulmonary Embolism, sponsored by Northwell Health.
- Active
- Registry status
- Phase 4
- Development phase
- 31
- Enrollment target
- 2
- Study locations
NCT03581877: Active Phase 4 study of Pulmonary Hypertension and Pulmonary Embolism, sponsored by Northwell Health.
NCT03581877 is a Phase 4 study of Pulmonary Hypertension and Pulmonary Embolism that is active but no longer recruiting, run by Northwell Health. The registered enrollment target is 31 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03581877, a Phase 4 study of Pulmonary Hypertension and Pulmonary Embolism, is active but no longer recruiting, sponsored by Northwell Health.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 31 participants
- Enrollment target
- 2
- Study locations
Study Summary
To determine whether peripheral low dose systemic thrombolysis (PLST) is non-inferior to catheter directed acoustic pulse thrombolysis (ACDT) in improving RV function and reducing pulmonary artery pressures in submassive pulmonary embolism (PE)
Primary Outcome
Investigators will measure and compare the change between baseline and 48 hours right ventricular diameter to left ventricular diameter (RV:LV ratio) on echocardiogram after PLST or ACDT
Conditions Studied
Interventions
- DRUG Alteplase
- DEVICE EKOS
Study Locations (2)
New York
- Southside Northwell Hospital - Bay Shore
- Long Island Jewish Medical Center - Queens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-01-28 |
| Est. Completion | 2025-03-19 |
| Phase | Phase 4 |
What the registry record for NCT03581877 still lists
NCT03581877 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (95% lower).
The record links to 4 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Alteplase is the first listed.
NCT03581877 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03581877 about?
NCT03581877 is a clinical study titled "Peripheral Systemic Thrombolysis Versus Catheter Directed Thrombolysis for Submassive PE". To determine whether peripheral low dose systemic thrombolysis (PLST) is non-inferior to catheter directed acoustic pulse thrombolysis (ACDT) in improving RV function and reducing pulmonary artery pressures in submassive pulmonary embolism (PE)
What is the current status of trial NCT03581877?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 31 participants. The study started on 2019-01-28. Estimated completion is 2025-03-19.
What conditions does trial NCT03581877 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Pulmonary Embolism, Thromboembolism, Right Ventricular Dysfunction.
What interventions are being tested in trial NCT03581877?
The interventions under investigation include: Alteplase (DRUG), EKOS (DEVICE).
Who is sponsoring clinical trial NCT03581877?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03581877 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03581877's enrollment target sits among peer trials
31 47th of 72 higher than 25 of 72 other Pulmonary Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Ranolazine in the Treatment of Pulmonary Hypertension Associated With Diastolic Left Ventricular Dysfunction
COMPLETED · Phase 4
-
Exercise Induced Pulmonary Hypertension in Systemic Sclerosis and Treatment With Ambrisentan
COMPLETED · Phase 4
-
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis
COMPLETED · Phase 4
-
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
RECRUITING
-
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
RECRUITING
-
Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI